NCT03928262View on ClinicalTrials.gov

Pharmacokinetic Study of Benralizumab in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 2, 2019

Primary Completion Date

August 12, 2019

Study Completion Date

August 12, 2019

Conditions
Healthy Subjects
Interventions
BIOLOGICAL

Benralizumab

Treatment 1: Benralizumab single dose, Treatment 2: Benralizumab single dose and Treatment 3: Benralizumab single dose subcutaneously administration on 36 healthy Chinese male and female subjects in 1:1:1 ratio.

Trial Locations (1)

Unknown

Research Site, Hong Kong

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY